Innovation Pharmaceuticals Inc.
IPIX · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.29 | -0.03 | 0.09 |
| FCF Yield | -10.92% | -3.68% | -4.89% | -5.26% |
| EV / EBITDA | -7.25 | -15.75 | -14.26 | -29.84 |
| Quality | ||||
| ROIC | -46.63% | -25.79% | -19.30% | -8.15% |
| Gross Margin | 0.00% | 1,650.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.54 | 0.67 | 1.32 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -78.56% | – | – |
| Free Cash Flow Growth | -78.22% | 21.60% | 3.57% | 36.60% |
| Safety | ||||
| Net Debt / EBITDA | 0.81 | 2.16 | 2.72 | 8.02 |
| Interest Coverage | -61.86 | -74.67 | -35.74 | -24.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,089.66 | -1,450.65 | -1,161.38 | 0.00 |